raloxifene hydrochloride has been researched along with osteoprotegerin in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Allan, GF; Clancy, J; Hutchins, A; Liu, X | 1 |
| Cheung, J; Evans, BA; Fogelman, I; Hampson, G; Mak, YT; Papaioannou, S | 1 |
| Blaschke, S; Emons, G; Frosch, KH; Gründker, C; Hofbauer, LC; Niederkleine, B; Raddatz, D; Siggelkow, H; Viereck, V | 1 |
| Bashir, A; Cheung, J; Fogelman, I; Grigoriadis, AE; Hampson, G; Mak, YT; McGowan, NW; Sankaralingam, S | 1 |
| Li, J; Tang, JG; Wu, HY; Wu, WK | 1 |
| Cafiero, A; Cobellis, L; Mainini, G; Messalli, EM; Ragucci, A; Salzillo, PL; Scaffa, C | 1 |
| Härkönen, PL; Hentunen, TA; Kangas, L; Michael, H; Väänänen, HK | 1 |
| Alonso, G; de la Higuera, M; Escobar-Jiménez, F; Fernández-García, D; Luna, JD; Mezquita-Raya, P; Muñoz-Torres, M; Ochoa, AS; Reyes-García, R; Ruiz-Requena, ME | 1 |
| Dias, SM; Dornelles, RC; Garcia, IR; Luvizuto, ER; Okamoto, R; Okamoto, T; Queiroz, TP | 1 |
| Gong, YX; Huang, L; Liu, JM; Lu, SY; Pang, XF; Wang, ZG; Xu, Y; Yan, MZ; Zhao, YJ | 1 |
| Giner, M; Miranda, C; Montoya, MJ; Pérez-Cano, R; Rios, MJ; Vázquez, MA | 1 |
| Akalin, S; Aydin, H; Deyneli, O; Tarçin, O; Tutepe, H; Yavuz, D; Yazici, D; Yüksel, M | 1 |
| Dias, SS; Dornelles, RC; Luvizuto, ER; Okamoto, R; Okamoto, T | 1 |
| Cano, A; García-Pérez, MÁ; Hermenegildo, C; Pineda, B; Tarín, JJ | 1 |
| Marc, J; Mencej-Bedrač, S; Mlakar, SJ; Preželj, J; Zavratnik, A; Zupan, J | 1 |
| de Oliveira Puttini, I; Faverani, LP; Luvizuto, ER; Momesso, GAC; Okamoto, R; Ramalho-Ferreira, G | 1 |
| Li, L; Li, LZ; Li, ZY; Sun, J; Sun, WJ; Wang, C; Wang, Y; Yu, LR; Zhang, YL; Zhao, Y | 1 |
| Borysewicz-Sanczyk, H; Karwowski, W; Koc-Żórawska, E; Lekesiz, K; Naumnik, B; Wnuczko, K | 1 |
| Goyal, R; Kumar, A; Saini, RV; Sharma, A; Sharma, L | 1 |
5 trial(s) available for raloxifene hydrochloride and osteoprotegerin
| Article | Year |
|---|---|
Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Topics: Aged; Bone Density; Bone Resorption; Carrier Proteins; Collagen; Collagen Type I; Estrogens; Female; Gene Expression Regulation; Glycoproteins; Hormone Replacement Therapy; Humans; Leukocytes, Mononuclear; Longitudinal Studies; Membrane Glycoproteins; Middle Aged; Osteoporosis; Osteoprotegerin; Peptides; Postmenopause; Raloxifene Hydrochloride; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; RNA, Messenger; Selective Estrogen Receptor Modulators | 2005 |
Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women.
Topics: Bone Density; Collagen; Female; Humans; Interleukin-6; Middle Aged; Osteoblasts; Osteoporosis, Postmenopausal; Osteoprotegerin; Peptide Fragments; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2007 |
Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.
Topics: Aged; Bone Density Conservation Agents; Calcium; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; Vitamin D | 2008 |
Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling.
Topics: Bone Density Conservation Agents; Bone Remodeling; Cell Proliferation; Cells, Cultured; Female; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-1beta; Interleukin-4; Interleukin-6; Leukocytes, Mononuclear; Lymphocyte Subsets; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; Raloxifene Hydrochloride; Receptor Activator of Nuclear Factor-kappa B; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2012 |
Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway.
Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Female; Humans; Osteoporosis, Postmenopausal; Osteoprotegerin; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Selective Estrogen Receptor Modulators; Wnt Signaling Pathway | 2014 |
14 other study(ies) available for raloxifene hydrochloride and osteoprotegerin
| Article | Year |
|---|---|
Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification.
Topics: Alkaline Phosphatase; Base Sequence; Bone and Bones; Branched DNA Signal Amplification Assay; Breast; Cell Line; Endothelium; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation; Glycoproteins; Humans; Inhibitory Concentration 50; Oligodeoxyribonucleotides; Osteoblasts; Osteoprotegerin; Raloxifene Hydrochloride; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Receptors, Progesterone; Receptors, Tumor Necrosis Factor; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Transcriptional Activation; Uterus | 2001 |
Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
Topics: Carrier Proteins; Cell Line; Cell Line, Transformed; Cytokines; Depression, Chemical; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Estradiol; Glycoproteins; Humans; Interleukin-1; Interleukin-6; Membrane Glycoproteins; Osteoblasts; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators | 2003 |
Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.
Topics: Adult; Alkaline Phosphatase; Anti-Inflammatory Agents; Cells, Cultured; Dexamethasone; DNA; Dose-Response Relationship, Drug; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Glycoproteins; Humans; Immunohistochemistry; Interleukin-6; Male; Osteoblasts; Osteoprotegerin; Procollagen; Protein Biosynthesis; Raloxifene Hydrochloride; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Receptors, Progesterone; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators; Trabecular Meshwork; Up-Regulation | 2003 |
[Effect of raloxifene and estradiol on the biological function and osteoprotegerin expression of osteoblasts in vitro].
Topics: Alkaline Phosphatase; Animals; Animals, Newborn; Cell Proliferation; Cells, Cultured; Estradiol; Osteoblasts; Osteoprotegerin; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley | 2005 |
Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Topics: Animals; Apoptosis; Bone Resorption; Cattle; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Dexamethasone; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Lipopolysaccharide Receptors; Macrophage Colony-Stimulating Factor; Monocytes; Osteoclasts; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Tumor Necrosis Factor-alpha | 2007 |
Histomorphometric analysis and immunolocalization of RANKL and OPG during the alveolar healing process in female ovariectomized rats treated with oestrogen or raloxifene.
Topics: Alveolar Process; Analysis of Variance; Animals; Estrogens; Female; Incisor; Osteoprotegerin; Ovariectomy; Raloxifene Hydrochloride; RANK Ligand; Rats; Rats, Wistar; Tooth Extraction; Wound Healing | 2010 |
Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cell Count; Elastic Modulus; Female; Femur; Gene Expression Regulation; Lumbar Vertebrae; Mechanical Phenomena; Mice; Mice, Knockout; Osteoclasts; Osteoprotegerin; Raloxifene Hydrochloride; Random Allocation; RANK Ligand; RNA, Messenger | 2010 |
Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Cells, Cultured; Estradiol; Female; Humans; Male; Middle Aged; Osteoarthritis; Osteoblasts; Osteoporosis, Postmenopausal; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; RNA, Messenger | 2011 |
Effect of oxidative stress on aorta and tibia osteoprotegerin gene expression in ovariectomized rats.
Topics: Animals; Aorta; Bone and Bones; Estradiol; Female; Malondialdehyde; Muscle, Smooth, Vascular; Osteoprotegerin; Ovariectomy; Oxidative Stress; Raloxifene Hydrochloride; Rats; Rats, Wistar; Reactive Oxygen Species; RNA, Messenger; Selective Estrogen Receptor Modulators; Tibia | 2011 |
Raloxifene therapy inhibits osteoclastogenesis during the alveolar healing process in rats.
Topics: Acid Phosphatase; Alveolar Process; Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Fibroblasts; Immunohistochemistry; Isoenzymes; Osteoblasts; Osteoclasts; Osteocytes; Osteoprotegerin; Ovariectomy; Raloxifene Hydrochloride; Random Allocation; RANK Ligand; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tartrate-Resistant Acid Phosphatase; Time Factors; Tooth Extraction; Tooth Socket; Wound Healing | 2011 |
Effect of antiresorptive drugs in the alveolar bone healing. A histometric and immunohistochemical study in ovariectomized rats.
Topics: Alendronate; Alveolar Process; Animals; Bone Density Conservation Agents; Female; Immunohistochemistry; Osteocalcin; Osteogenesis; Osteoprotegerin; Ovariectomy; Raloxifene Hydrochloride; RANK Ligand; Rats; Rats, Wistar; Tartrate-Resistant Acid Phosphatase; Wound Healing | 2017 |
Daidzein increases OPG/RANKL ratio and suppresses IL-6 in MG-63 osteoblast cells.
Topics: Cell Line; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Fulvestrant; Humans; Interleukin-6; Isoflavones; Nuclear Receptor Coactivator 1; Osteoblasts; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; RNA, Small Interfering | 2016 |
Effects of 17β-estradioland raloxifene on endothelial OPG and RANKL secretion.
Topics: Endothelial Cells; Estradiol; Estrogens; Female; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Osteoprotegerin; Postmenopause; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Vascular Calcification | 2017 |
Pinus roxburghii alleviates bone porosity and loss in postmenopausal osteoporosis by regulating estrogen, calcium homeostasis and receptor activator of nuclear factor-κB, osteoprotegerin, cathepsin bone markers.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cathepsins; Cell Proliferation; Estrogens; Female; Humans; Osteoblasts; Osteoporosis, Postmenopausal; Osteoprotegerin; Pinus; Plant Extracts; Porosity; Raloxifene Hydrochloride; Rats; Receptor Activator of Nuclear Factor-kappa B; Treatment Outcome | 2021 |